Roche bets on Zion HER2 brain metastases prospect
09 May 2023
License out/inPhase 1ADC
Roche has acquired the global rights to Chinese biotech Zion Pharma's lead program, a drug designed to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancerHER2-positive metastatic breast cancer.
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). According to Zion, up to 50% of patients with HER2-positive metastatic breast cancerHER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease. ZN-A-104, which is currently in phase 1 trials in China and the U.S., was designed to be blood-brain-barrier-penetrant.
Per the deal, Roche will take on the development, manufacturing and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million upfront and will also be eligible for up to $610 million in additional payments following achievement of certain development, regulatory and sales-based milestones.
HER2 has become an increasingly popular target for drugmakers in the cancer space and many are looking to Chinese biotechs for partnering opportunities. Back in April, BioNTech signed a $1.5 billion deal with China-based biotech DualityBio to co-develop and commercialize two cancer ADCs candidates, including DualityBio’s lead candidate, DB-1303, which is a topoisomerase-1 inhibitor-based ADC directed against HER2. Eisai and China-based Bliss Biopharmaceutical just announced a clinical trial collaboration agreement — with the option to license — for BlissBio's ADC candidate directed against HER2 for the treatment of cancers.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.